Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03981380 · ClinicalTrials.gov registry record
11C-PIB PET Study in MESA at Columbia University
A clinical trial of Alzheimer Disease and Cognitive Impairment, sponsored by José A. Luchsinger.
- Completed
- Registry status
- 59
- Enrollment target
- 1
- Study location
NCT03981380 is a study of Alzheimer Disease and Cognitive Impairment that has completed, run by José A. Luchsinger. The registered enrollment target is 59 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03981380, a study of Alzheimer Disease and Cognitive Impairment, has completed, sponsored by José A. Luchsinger.
- COMPLETED
- Registry status
- 59 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators will conduct a study of brain positron emission tomography (PET) using 11C-PIB for the imaging of brain amyloid in 250 participants in the Multiethnic study of atherosclerosis (MESA) at Columbia University Irving Medical Center in New York City. Participants will be imaged only once with Pittsburgh Compound B (PIB) PET.
Conditions Studied
Interventions
- DRUG 11C-PIB
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2020-08-01 |
| Est. Completion | 2024-02-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03981380
The ClinicalTrials.gov registry entry for NCT03981380 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (98% lower). The listed sponsor is José A. Luchsinger, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which 11C-PIB is the first listed.
NCT03981380 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03981380 about?
NCT03981380 is a clinical study titled "11C-PIB PET Study in MESA at Columbia University". The investigators will conduct a study of brain positron emission tomography (PET) using 11C-PIB for the imaging of brain amyloid in 250 participants in the Multiethnic study of atherosclerosis (MESA) at Columbia University Irving Medical Center in New York City. Participants will be imaged only onc...
What is the current status of trial NCT03981380?
This trial is currently completed. The enrollment target is 59 participants. The study started on 2020-08-01. Estimated completion is 2024-02-05.
What conditions does trial NCT03981380 study?
This clinical trial studies the following conditions: Alzheimer Disease, Cognitive Impairment, Atherosclerosis, Vascular Diseases.
What interventions are being tested in trial NCT03981380?
The interventions under investigation include: 11C-PIB (DRUG).
Who is sponsoring clinical trial NCT03981380?
This trial is sponsored by José A. Luchsinger, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03981380 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.